 Izakibab is a new drug candidate that shows promise in treating psoriasis, psoriatic arthritis, axial spondylarthritis, hydrodinitis supporativa, and uviitis. It works by binding to and neutralizing the effects of interleukin 17a, a protein that plays a major role in these diseases. This drug has been shown to be safe and effective in clinical trials, and it may provide a better alternative than current treatments. This article was authored by Suzanne Clint, Joachim Feldwisch, Lindvig Gudman's daughter, and others.